{"id":76440,"date":"2026-05-06T20:43:00","date_gmt":"2026-05-06T20:43:00","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/76440\/"},"modified":"2026-05-06T20:43:00","modified_gmt":"2026-05-06T20:43:00","slug":"novo-nordisk-nvo-lifts-2026-outlook-as-obesity-drug-demand-remains-strong","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/76440\/","title":{"rendered":"Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strong"},"content":{"rendered":"

\"Wegovy Wegovy \u00a9Novo Nordisk <\/p>\n

Novo Nordisk (NYSE:NVO) raised its full-year guidance on Wednesday, citing continued strong demand for its obesity and diabetes treatments despite softer underlying first-quarter results caused by pricing pressure.<\/p>\n

The pharmaceutical group said it now expects adjusted sales and operating profit for 2026 to decline between 4% and 12% at constant exchange rates, representing a narrower contraction than previously anticipated and reflecting stronger expectations for its GLP-1 treatment portfolio.<\/p>\n

Shares in the Danish drugmaker climbed 7% in early trading in Copenhagen.<\/p>\n

First-quarter results boosted by one-off U.S. pricing adjustment <\/p>\n

Operating profit in the first quarter jumped 65% to 59.6 billion Danish crowns ($8.6 billion), supported by a one-time reversal related to the U.S. 340B Drug Pricing Program.<\/p>\n

However, on an adjusted basis, operating profit fell 6% to 32.9 billion crowns, while adjusted revenue declined 4% to 70.1 billion crowns as lower realised prices offset growth in sales volumes.<\/p>\n

Wegovy continues to drive obesity treatment growth <\/p>\n

Sales of obesity therapies remained a key growth driver for the company, rising 22% at constant exchange rates, helped by continued demand for Wegovy.<\/p>\n

The newly launched oral version of Wegovy in the United States generated quarterly sales of 2.3 billion Danish crowns.<\/p>\n

Adjusted sales in the U.S. market declined 11% because of pricing headwinds, while international sales increased 6% on the back of stronger volumes.<\/p>\n

Analysts remain optimistic on guidance outlook <\/p>\n

\u201cWe continue to see the bottom end of the guidance as conservative and expect Novo to finish the year in the upper half of the guidance,\u201d analysts at Morgan Stanley said in a research note.<\/p>\n

Novo Nordisk stated that broader access to GLP-1 medicines and ongoing product launches should continue to support growth, although increased competition, pricing pressure and patent expirations are expected to weigh on performance during the remainder of the year.<\/p>\n

Novo Nordisk stock price<\/p>\n","protected":false},"excerpt":{"rendered":"Wegovy \u00a9Novo Nordisk Novo Nordisk (NYSE:NVO) raised its full-year guidance on Wednesday, citing continued strong demand for its…\n","protected":false},"author":2,"featured_media":76441,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[7736,583,5219,272,357,4165,40897],"class_list":{"0":"post-76440","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-adjusted-basis","9":"tag-danish-crowns","10":"tag-exchange-rates","11":"tag-novo-nordisk","12":"tag-obesity","13":"tag-operating-profit","14":"tag-quarterly-sales"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116529581618308195","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/76440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=76440"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/76440\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/76441"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=76440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=76440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=76440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}